Correction: J Exp Clin Cancer Res 41, 284 (2022) https://doi.org/10.1186/s13046-022-02493-0

Following publication of the original article [1], an error was identified in Fig. 6; specifically:

  • Figure 6E: The flow cytometry image of group HT29 sh2 + erastin

  • Figure 6F: The group label “sh3” should be corrected into “sh2”

Fig. 6
figure 1

AADAC upregulates SLC7A11 by activating NRF2. A Protein expression of SLC7A11 upstream genes in sh-AADAC cells. B Protein expression of SLC7A11 in shNC, sh-AADAC and sh-AADAC + 10 µM TBHQ HCT116 cells. C Relative MDA levels in shNC, sh-AADAC, and sh-AADAC + 10 µM TBHQ HCT116 cells treated with 15 µM erastin, and in SW480 cells (control, ADOE, ADOE + ML385) treated with 15 µM erastin. D Relative GSH level, GSSG level and GSH/GSSG ratio of HCT116 cells (shNC, shNC + 10 µM TBHQ, and sh-AADAC + 10 µM TBHQ) and SW480 cells (control, control + ML385, ADOE + ML385). E Relative levels of lipid ROS in HCT116 and HT29 cells pretreated with or without 10 µM TBHQ for 1 h, and with 15 µM erastin for 48 h. F Data are shown as the mean ± SD. Significance was calculated by a two-tailed ratio t test (C, D, F). p value < 0.001 (***), p value < 0.01 (**), p value < 0,05 (*), ns (not significant)

The correct figure is now been provided. The correction does not have any effect on the results or conclusions of the paper. The original article has been corrected.